-
Donaldson Charitable Trust targets multiple myeloma
Multiple myeloma (MM), a blood cancer diagnosed in about 35,000 Americans each year, is the focus of three recent grants totaling $708,106 from the Donaldson Charitable Trust.
-
CRI grants accelerate immunotherapy research at Dana-Farber
The Cancer Research Institute (CRI) is advancing bold new strategies to harness the immune system against cancer through two grants at Dana-Farber Cancer Institute.
-
IBC Network Foundation
The IBC Network Foundation made a generous $100,000 gift to advance the inflammatory breast cancer (IBC) research of Filipa Lynce, MD, FASCO. With this, Lynce will explore the ability of T-cell receptors to predict response to immunotherapy and drive progress in the treatment of IBC, which will ultimately offer hope to patients with this rare…
-
International Myeloma Society
Dana-Farber Cancer Institute’s Mohammad Rashidian, PhD, received a $250,000 Translational Research Award from the International Myeloma Society and the Paula and Rodger Riney Foundation. This support will advance his innovative work to combat disease relapse in multiple myeloma patients following CAR T-cell therapy.
-
Melanoma Research Alliance
Since its founding in 2007, the Melanoma Research Alliance has become the largest nonprofit funder of crucial melanoma research worldwide. In 2025, they awarded $430,000 in grants to Dana-Farber Cancer Institute supporting the work of Rizwan Haq, MD, PhD, Giacomo Oliveira, PhD, and David Liu, MD, MPH, MS, to advance the studies of uveal melanoma…
-
The Terri Brodeur Breast Cancer Foundation
The Terri Brodeur Breast Cancer Foundation awarded $125,000 to Genevra Kuziel, PhD, supporting her research on estrogen receptor-positive (ER+) breast cancer, the most common breast cancer subtype with a high recurrence rate. Kuziel’s work aims to develop innovative combination therapies, with the goal of transforming treatment options and improving outcomes for patients.
-
International Cancer Advocacy Network
The Exon 20 Group's International Research Consortium at the International Cancer Advocacy Network (ICAN) awarded $100,000 to Michael Eck, MD, PhD, to improve our understanding of common EGFR exon 20 insertion variants, which will be valuable for the development of potent and selective inhibitors for EGFR-mutant non-small cell lung cancer. This funding can accelerate the…
-
Lymphoma Research Foundation
The Lymphoma Research Foundation awarded Dana-Farber Cancer Institute's Tianfang Ma, PhD, a generous $195,000 Postdoctoral Fellowship Grant, to bolster his research and growth as an independent investigator. Ma’s work focuses on the tumor immune microenvironment in diffuse large B-cell lymphoma and may help enhance immunotherapy effectiveness and identify predictive markers to improve patient outcomes.
-
St. Baldrick’s Foundation
St. Baldrick’s Foundation awarded a $195,000 fellowship grant to Geoffrey Smith, MD, PhD, to try to identify mechanisms of immune evasion in models of osteosarcoma using next generation sequencing and cutting-edge technologies to study the response of single cells. Based on these findings, he will test novel immunotherapies to prioritize the next generation of osteosarcoma…
-
Russ Agrusa honors late wife by fueling colorectal cancer research
Russ and his late wife, Paula, established the Project P Fund in 2014 with a goal of empowering researchers at Dana-Farber to develop more effective targeted and immune-based therapies for patients with colorectal cancer. Since Paula’s death in 2016, Russ has continued to honor her legacy through ongoing support for the Project P Fund. With…
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.